Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
213 hedge funds and large institutions have $4.41B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2015 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 77 increasing their positions, 60 reducing their positions, and 33 closing their positions.
200% more call options, than puts
Call options by funds: $148M | Put options by funds: $49.4M
112% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 33
72% more capital invested
Capital invested by funds: $2.57B → $4.41B (+$1.84B)
28% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 60
20% more funds holding
Funds holding: 177 → 213 (+36)
20% more funds holding in top 10
Funds holding in top 10: 15 → 18 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$422M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$121M |
| 3 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$97.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94.3M |
| 5 |
JP Morgan Chase
New York
|
+$72.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$68.3M |
| 2 |
TCP
Tourbillon Capital Partners
New York
|
-$52.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$45.2M |
| 4 |
VAM
Visium Asset Management
New York
|
-$39M |
| 5 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$38.1M |
HZNP Hedge Fund Activity: Q2 2015 in Review
213 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2015, worth a combined $4.41B — up 72% from $2.57B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new HZNP positions and 33 closed out — a net gain of 37 holders — while 77 added to existing stakes and 60 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $422M. The largest seller was Broadfin Capital, cutting an estimated $68.3M.
- 213 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2015, up from 177 in Q1 2015.
- Funds reported $4.41B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2015, up 72% quarter-over-quarter.
- 70 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2015 and 33 closed out, a net change of +37 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2015 was Fidelity Investments, an estimated $422M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2015 was Broadfin Capital, an estimated $68.3M sold.
Based on aggregated 13F filings for Q2 2015.